Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Aprepitant

FDA-approved product (capsule, oral), marketed as Aponvie, Aprepitant, Cinvanti and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Aprepitant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chemotherapy-induced nausea and vomiting
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antiemetics
FDA pharmacologic class
Substance P/Neurokinin-1 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Aprepitant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Aprepitant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous Administration

    NCT07817004 · start 2026-09

    Registered record
    Registry ID
    NCT07817004
    Conditions
    Chemotherapy-Induced Nausea and Vomiting (CINV)
    Interventions
    apripitant and palonosetron injectable emulsion; palonosetron hydrochloride injection; apripitant injection (CINVANTI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2026-12
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting (CINV)
    Interventionapripitant and palonosetron injectable emulsion; palonosetron hydrochloride injection; apripitant injection (CINVANTI)
    PhasePhase 1
    Registry statusNot yet recruiting

  • A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy

    NCT07662200 · start 2026-08

    Registered record
    Registry ID
    NCT07662200
    Conditions
    Germ Cell Cancer
    Interventions
    Netupitant/Palonosetron Hydrochloride; Ondansetron (Control); Aprepitant; Dexamethasone; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2026-08
    Completion
    2028-08
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGerm Cell Cancer
    InterventionNetupitant/Palonosetron Hydrochloride; Ondansetron (Control); Aprepitant; Dexamethasone +1 more
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Aprepitant to Improve Same Day Discharge for TKA

    NCT07639723 · start 2026-07

    Registered record
    Registry ID
    NCT07639723
    Conditions
    PONV
    Interventions
    Aprepitant Injection; Ondansetron (Zofran); Dexamethasone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-07
    Completion
    2027-08
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPONV
    InterventionAprepitant Injection; Ondansetron (Zofran); Dexamethasone; Placebo
    PhasePhase 4
    Registry statusNot yet recruiting

  • Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients

    NCT06931119 · start 2025-05-30

    Registered record
    Registry ID
    NCT06931119
    Conditions
    Pruritus
    Interventions
    EMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2025-05-30
    Completion
    2026-12-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPruritus
    InterventionEMEND® (EE mend) (aprepitant) capsules (80mg +125mg) Marketing Authorization Holder and Importer: Merck Sharp & Dohme (Israel-1996) Company Ltd.
    PhasePhase 1
    Registry statusNot yet recruiting

  • To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

    NCT07081256 · start 2025-01-03

    Registered record
    Registry ID
    NCT07081256
    Conditions
    Chemotherapy-Induced Nausea and Vomiting
    Interventions
    QLM2010 for injection；dexamethasone; fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2025-01-03
    Completion
    2025-10-15
    Enrolment
    665

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-Induced Nausea and Vomiting
    InterventionQLM2010 for injection；dexamethasone; fosaprepitant dimeglumine for injection；palonosetron hydrochloride injection；dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting

    NCT06593782 · start 2024-09-16

    Registered record
    Registry ID
    NCT06593782
    Conditions
    Nausea and Vomiting, Chemotherapy-Induced
    Interventions
    HSK21542; HSK21542; Dolasetron
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2024-09-16
    Completion
    2025-09-01
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting, Chemotherapy-Induced
    InterventionHSK21542; HSK21542; Dolasetron
    PhasePhase 2
    Registry statusNot yet recruiting

  • Aprepitant and Ondansetron Monotherapy or Combination for Postoperative Nausea and Vomiting in Thyroid Cancer

    NCT06697782 · start 2024-07-01

    Registered record
    Registry ID
    NCT06697782
    Conditions
    Thyroid Cancer
    Interventions
    Ondansetron 8mg; Aprepitant 125 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-07-01
    Completion
    2025-01-01
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThyroid Cancer
    InterventionOndansetron 8mg; Aprepitant 125 mg
    PhasePhase 4
    Registry statusCompleted

  • Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention

    NCT05773950 · start 2023-08-18

    Registered record
    Registry ID
    NCT05773950
    Conditions
    Postoperative Nausea and Vomiting; Gynecologic Surgical Procedures; Laparoscopy
    Interventions
    fosaprepitant; normal saline
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Enrolling by invitation
    Start
    2023-08-18
    Completion
    2025-12
    Enrolment
    144

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Nausea and Vomiting; Gynecologic Surgical Procedures; Laparoscopy
    Interventionfosaprepitant; normal saline
    PhaseNot applicable
    Registry statusEnrolling by invitation

  • Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data

    NCT04606264 · start 2023-05-15

    Registered record
    Registry ID
    NCT04606264
    Conditions
    Perioperative Optimization
    Interventions
    Neuraxial Analgesia; Regional Block 1: Paravertebral; Perphenazine; Aprepitant; Dimenhydrinate; Ondansetron 4 MG; Dexamethasone; Regional Block 2: QL1
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2023-05-15
    Completion
    2025-03-21
    Enrolment
    3,395

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerioperative Optimization
    InterventionNeuraxial Analgesia; Regional Block 1: Paravertebral; Perphenazine; Aprepitant +4 more
    PhasePhase 3
    Registry statusCompleted

  • 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

    NCT05317000 · start 2023-03-23

    Registered record
    Registry ID
    NCT05317000
    Conditions
    Squamous Cell Carcinoma of Head and Neck
    Interventions
    Combination 5-azacytidine and nivolumab; Nivolumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-03-23
    Completion
    2028-11-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Carcinoma of Head and Neck
    InterventionCombination 5-azacytidine and nivolumab; Nivolumab
    PhasePhase 2
    Registry statusRecruiting

  • Granisetron Transdermal Patch for Prophylaxis of Delayed CINV

    NCT04912271 · start 2021-06-10

    Registered record
    Registry ID
    NCT04912271
    Conditions
    Chemotherapy-induced Nausea and Vomiting (CINV)
    Interventions
    Granisetron transdermal patch; Palonosetron; Aprepitant; Fosaprepitant; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2021-06-10
    Completion
    2023-12-30
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChemotherapy-induced Nausea and Vomiting (CINV)
    InterventionGranisetron transdermal patch; Palonosetron; Aprepitant; Fosaprepitant +1 more
    PhasePhase 3
    Registry statusUnknown

  • Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3

    NCT04649229 · start 2021-05-27

    Registered record
    Registry ID
    NCT04649229
    Conditions
    Heart Failure
    Interventions
    LCZ 696; Placebo; Para-aminohippurate; Iohexol; Aprepitant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2021-05-27
    Completion
    2025-05-22
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionLCZ 696; Placebo; Para-aminohippurate; Iohexol +1 more
    PhasePhase 4
    Registry statusCompleted

  • The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs

    NCT05202275 · start 2020-12-01

    Registered record
    Registry ID
    NCT05202275
    Conditions
    Nausea; Vomiting; Head and Neck Squamous Cell Carcinoma; Radiotherapy Side Effect
    Interventions
    Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2020-12-01
    Completion
    2023-09
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea; Vomiting; Head and Neck Squamous Cell Carcinoma; Radiotherapy Side Effect
    InterventionOlanzapine
    PhasePhase 2
    Registry statusUnknown

  • Effects of Aprepitant/Dexamethasone Versus Mertazepine /Dexamethasone on Postoperative Nausea and Vomiting

    NCT04013386 · start 2019-07-15

    Registered record
    Registry ID
    NCT04013386
    Conditions
    Nausea and Vomiting, Postoperative
    Interventions
    Aprepitant and Dexamethasone; Mirtazapine and Dexamethasone; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-07-15
    Completion
    2019-12-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting, Postoperative
    InterventionAprepitant and Dexamethasone; Mirtazapine and Dexamethasone; Dexamethasone
    PhasePhase 4
    Registry statusCompleted

  • Olanzapine Versus Aprepitant Based Antiemetic Regimen for High Emetic Chemotherapy

    NCT03876938 · start 2019-03-01

    Registered record
    Registry ID
    NCT03876938
    Conditions
    Antiemetic for Highly Emetogenic Chemotherapy
    Interventions
    aprepitant; olanzapine 10 mg; olanzapine 5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2019-03-01
    Completion
    2020-12
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntiemetic for Highly Emetogenic Chemotherapy
    Interventionaprepitant; olanzapine 10 mg; olanzapine 5 mg
    PhasePhase 3
    Registry statusUnknown